Puma Biotechnology (PBYI) Operating Leases (2019 - 2026)

Puma Biotechnology's Operating Leases history runs 8 years deep, the most recent figure standing at $4.5 million for Q1 2026.

• Quarterly Operating Leases fell 20.77% year-over-year to $4.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.5 million (down 20.77% YoY) and the FY2025 annual result came in at $4.7 million, up 215.19% from the prior year.
• Operating Leases was $4.5 million for Q1 2026 at Puma Biotechnology, down from $4.7 million in the prior quarter.
• Across five years, Operating Leases topped out at $15.0 million in Q1 2022 and bottomed at $1.5 million in Q4 2024.
• A 5-year average of $8.9 million and a median of $8.3 million in 2024 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2024 — Operating Leases slumped 78.76% — and 2025, when it soared 215.19%.
• Puma Biotechnology's Operating Leases stood at $11.8 million in 2022, then sank by 40.56% to $7.0 million in 2023, then slumped by 78.76% to $1.5 million in 2024, then surged by 215.19% to $4.7 million in 2025, then retreated by 3.46% to $4.5 million in 2026.
• Business Quant data shows PBYI's Operating Leases at $4.5 million in Q1 2026, $4.7 million in Q4 2025, and $4.9 million in Q3 2025.